{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:50:27Z","timestamp":1791499827277,"version":"4.3.4"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Biotechnology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.copbio.2019.11.020","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T12:34:28Z","timestamp":1576240468000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["Bispecific antibodies in cancer immunotherapy"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-3454","authenticated-orcid":false,"given":"Christoph","family":"Rader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.copbio.2019.11.020_sbref0005","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.copbio.2019.11.020_sbref0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific antibody based therapeutics: strengths and challenges","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.copbio.2019.11.020_bib0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the\u2019 high-hanging fruit\u2019","volume":"17","author":"Carter","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.copbio.2019.11.020_bib0020","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev-med-062617-035821","article-title":"Redirected T cell cytotoxicity in cancer therapy","volume":"70","author":"Clynes","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.copbio.2019.11.020_bib0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","article-title":"Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety","volume":"154","author":"Ellerman","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.copbio.2019.11.020_bib0030","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2019.11.020_bib0035","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0040","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2018-12-852376","article-title":"Taking a \"BiTE out of ALL\": blinatumomab approval for MRD-positive ALL","volume":"133","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.copbio.2019.11.020_bib0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","article-title":"FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease","volume":"25","author":"Jen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0050","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.copbio.2019.11.020_bib0055","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.copbio.2019.11.020_bib0060","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2017-09-804658","article-title":"Health-related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab","volume":"131","author":"Topp","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.copbio.2019.11.020_bib0065","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.copbio.2019.11.020_sbref0070","doi-asserted-by":"crossref","DOI":"10.3390\/antib8030041","article-title":"Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells","volume":"8","author":"Strohl","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.copbio.2019.11.020_bib0075","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2019.11.020_bib0080","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood-2018-01-785840","article-title":"Chimeric antigen receptor-modified T cells: CD19 and the road beyond","volume":"131","author":"Salter","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.copbio.2019.11.020_bib0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.copbio.2019.11.020_bib0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/hum.2017.254","article-title":"CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications","volume":"29","author":"Kohl","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.copbio.2019.11.020_bib0095","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.copbio.2019.11.020_bib0100","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.copbio.2019.11.020_bib0105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.copbio.2019.11.020_bib0110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2016.391","article-title":"Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors","volume":"31","author":"Aldoss","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.copbio.2019.11.020_sbref0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2018.08.010","article-title":"Building blocks for bispecific and trispecific antibodies","volume":"154","author":"Wu","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.copbio.2019.11.020_bib0120","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1158\/2326-6066.CIR-19-0121","article-title":"Silencing Fc domains in T cell-engaging bispecific antibodies improves T-cell trafficking and antitumor potency","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.copbio.2019.11.020_sbref0125","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-02-830992","article-title":"A CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.copbio.2019.11.020_sbref0130","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0135","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2019.11.020_bib0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.copbio.2019.11.020_bib0145","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.copbio.2019.11.020_bib0150","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.copbio.2019.11.020_bib0155","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.copbio.2019.11.020_bib0160","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-19-0007","article-title":"Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma","volume":"18","author":"Panowski","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.copbio.2019.11.020_bib0165","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"Gamma-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.copbio.2019.11.020_bib0170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymeth.2018.07.013","article-title":"Preparation of bispecific antibody-protein adducts by site-specific chemo-enzymatic conjugation","volume":"154","author":"Bartels","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.copbio.2019.11.020_sbref0175","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/0008-5472.CAN-18-0189","article-title":"A chemo-enzymatically linked bispecific antibody retargets T cells to a sialylated epitope on CD43 in acute myeloid leukemia","volume":"79","author":"Bartels","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0180","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","article-title":"Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies","volume":"31","author":"Anderson","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.copbio.2019.11.020_bib0185","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/imt-2018-0111","article-title":"Enhancing tumor T cell infiltration to enable cancer immunotherapy","volume":"11","author":"Zhang","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.copbio.2019.11.020_bib0190","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4291","article-title":"An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors","volume":"9","author":"Ishiguro","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.copbio.2019.11.020_bib0195","doi-asserted-by":"crossref","first-page":"E5467","DOI":"10.1073\/pnas.1719905115","article-title":"Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1","volume":"115","author":"Qi","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.copbio.2019.11.020_bib0200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat1445","article-title":"p95HER2-T cell bispecific antibody for breast cancer treatment","volume":"10","author":"Rius Ruiz","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.copbio.2019.11.020_sbref0205","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7534","article-title":"A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer","volume":"11","author":"Crawford","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.copbio.2019.11.020_bib0210","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3389\/fimmu.2017.01001","article-title":"Therapeutic antibodies against intracellular tumor antigens","volume":"8","author":"Trenevska","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.copbio.2019.11.020_bib0215","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97805","article-title":"TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies","volume":"3","author":"Ahmed","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.copbio.2019.11.020_bib0220","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-46198-5","article-title":"High throughput development of TCR-mimic antibody that targets survivin-2B80-88\/HLA-A\u2022A24 and its application in a bispecific T-cell engager","volume":"9","author":"Kurosawa","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.copbio.2019.11.020_bib0225","article-title":"Probody therapeutics: an emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology","author":"Autio","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0230","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41587-019-0135-x","article-title":"A coiled-coil masking domain for selective activation of therapeutic antibodies","volume":"37","author":"Trang","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.copbio.2019.11.020_bib0235","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1158\/1078-0432.CCR-17-0126","article-title":"A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma","volume":"24","author":"Gedeon","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0240","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.copbio.2019.11.020_bib0245","article-title":"Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events","author":"Klinger","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0250","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fonc.2018.00285","article-title":"Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy","volume":"8","author":"Kobold","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.copbio.2019.11.020_bib0255","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/0008-5472.CAN-16-3431","article-title":"Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells","volume":"77","author":"Chang","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0260","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.4049\/jimmunol.1801472","article-title":"LILRB1 blockade enhances bispecific T cell engager antibody-induced tumor cell killing by effector CD8(+) T cells","volume":"203","author":"Kim","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.copbio.2019.11.020_sbref0265","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5989","article-title":"Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy","volume":"11","author":"Claus","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.copbio.2019.11.020_bib0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07195-w","article-title":"A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity","volume":"9","author":"Compte","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.copbio.2019.11.020_bib0275","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3389\/fimmu.2019.01791","article-title":"Carcinoembryonic antigen (CEA)-specific 4-1BB-costimulation induced by CEA-targeted 4-1BB-agonistic trimerbodies","volume":"10","author":"Mikkelsen","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.copbio.2019.11.020_bib0280","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1158\/1078-0432.CCR-17-3123","article-title":"A T-cell-engaging B7-H4\/CD3-bispecific Fab-scFv antibody targets human breast cancer","volume":"25","author":"Iizuka","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0285","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.copbio.2019.11.020_bib0290","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.copbio.2019.11.020_bib0295","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3389\/fimmu.2018.02103","article-title":"Oncolytic viruses partner with T-cell therapy for solid tumor treatment","volume":"9","author":"Rosewell Shaw","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.copbio.2019.11.020_bib0300","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","article-title":"Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy","volume":"77","author":"Fajardo","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0305","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1158\/1078-0432.CCR-17-2651","article-title":"Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors","volume":"24","author":"Speck","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0310","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","article-title":"An Oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells","volume":"78","author":"Freedman","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0315","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40425-019-0505-4","article-title":"Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager","volume":"7","author":"de Sostoa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.copbio.2019.11.020_bib0320","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0325","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.it.2019.01.008","article-title":"T cell-redirecting strategies to\u2019 STAb\u2019 tumors: beyond CARs and bispecific antibodies","volume":"40","author":"Blanco","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1016\/j.copbio.2019.11.020_bib0330","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nm.4356","article-title":"Elimination of large tumors in mice by mRNA-encoded bispecific antibodies","volume":"23","author":"Stadler","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.copbio.2019.11.020_sbref0335","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126086","article-title":"DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity","volume":"4","author":"Perales-Puchalt","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.copbio.2019.11.020_bib0340","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2326-6066.CIR-17-0171","article-title":"CD28 and 41BB costimulation enhances the effector function of CD19-specific engager T cells","volume":"5","author":"Velasquez","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.copbio.2019.11.020_sbref0345","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.copbio.2019.11.020_bib0350","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fonc.2019.00176","article-title":"The emergence of universal immune receptor T cell therapy for cancer","volume":"9","author":"Minutolo","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.copbio.2019.11.020_bib0355","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00262-019-02399-5","article-title":"Conventional CARs versus modular CARs","volume":"68","author":"Feldmann","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.copbio.2019.11.020_bib0360","doi-asserted-by":"crossref","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","article-title":"Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory","volume":"115","author":"Viaud","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.copbio.2019.11.020_bib0365","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1158\/1078-0432.CCR-18-3927","article-title":"Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy","volume":"25","author":"Karches","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0370","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","article-title":"Harnessing innate immunity in cancer therapy","volume":"574","author":"Demaria","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.copbio.2019.11.020_bib0375","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1172\/JCI129338","article-title":"Killers 2.0: NK cell therapies at the forefront of cancer control","volume":"129","author":"Hodgins","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.copbio.2019.11.020_bib0380","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 Trispecific Killer Engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0385","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1182\/bloodadvances.2017012369","article-title":"161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS","volume":"2","author":"Sarhan","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.copbio.2019.11.020_bib0390","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.copbio.2019.11.020_bib0395","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","article-title":"Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity","volume":"177","author":"Gauthier","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.copbio.2019.11.020_bib0400","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","article-title":"Phagocytosis checkpoints as new targets for cancer immunotherapy","volume":"19","author":"Feng","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.copbio.2019.11.020_bib0405","doi-asserted-by":"crossref","first-page":"E10578","DOI":"10.1073\/pnas.1710877114","article-title":"Anti-SIRPalpha antibody immunotherapy enhances neutrophil and macrophage antitumor activity","volume":"114","author":"Ring","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.copbio.2019.11.020_bib0410","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1158\/1535-7163.MCT-17-1095","article-title":"Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia","volume":"17","author":"Buatois","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.copbio.2019.11.020_bib0415","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1386361","article-title":"CD20-selective inhibition of CD47-SIRPalpha \"don't eat me\" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab","volume":"7","author":"van Bommel","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.copbio.2019.11.020_bib0420","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3389\/fimmu.2018.02203","article-title":"Complement as a biological tool to control tumor growth","volume":"9","author":"Macor","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.copbio.2019.11.020_bib0425","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/leu.2014.185","article-title":"Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice","volume":"29","author":"Macor","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.copbio.2019.11.020_bib0430","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activate3d by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.copbio.2019.11.020_bib0435","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3324\/haematol.2018.207266","article-title":"CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering","volume":"104","author":"Oostindie","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.copbio.2019.11.020_bib0440","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3324\/haematol.2019.224196","article-title":"Six-packed antibodies punch better","volume":"104","author":"Rader","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.copbio.2019.11.020_bib0445","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48461-1","article-title":"A novel bispecific antibody platform to direct complement activity for efficient lysis of target cells","volume":"9","author":"Cruz","year":"2019","journal-title":"Sci Rep"}],"container-title":["Current Opinion in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958166919301363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958166919301363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:07:46Z","timestamp":1760692066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0958166919301363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":89,"alternative-id":["S0958166919301363"],"URL":"https:\/\/doi.org\/10.1016\/j.copbio.2019.11.020","relation":{},"ISSN":["0958-1669"],"issn-type":[{"value":"0958-1669","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific antibodies in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.copbio.2019.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}